#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Veterinarians in Maryland may soon be able to recommend cannabis products for pets, which creates potential parallels to human medical cannabis use that clinicians should understand when counseling pet-owning patients about treatment options and drug interactions. This regulatory shift reflects growing interest in cannabis therapeutics across species, making it important for clinicians to stay informed about evidence, safety profiles, and legal status of these products to provide accurate guidance to patients seeking alternative treatments for their animals. Understanding veterinary cannabis approval in their jurisdiction helps clinicians address patient questions about cannabis efficacy and safety more credibly while recognizing the gaps in clinical evidence that currently exist for both human and animal applications.
Maryland’s proposed legislation would permit veterinarians to recommend cannabis products for dogs and cats, paralleling the expansion of medical cannabis access in human medicine. This regulatory change reflects growing interest in cannabinoid-based therapeuties for veterinary conditions, potentially including pain management, anxiety, and seizure control in companion animals. However, veterinarians considering cannabis recommendations for pets should recognize that evidence for safety and efficacy in animals remains limited compared to human clinical research, and products are not FDA-approved for veterinary use. The lack of standardized dosing, quality control, and long-term safety data in animal populations creates clinical uncertainty that must be carefully weighed against potential therapeutic benefits. Clinicians should stay informed about evolving veterinary cannabis regulations in their states, as these developments may influence patient conversations about treatment options for their pets and underscore the broader need for rigorous clinical research in both human and veterinary cannabinoid medicine. For now, veterinarians and physicians should exercise caution in recommending cannabis for animals until robust evidence and regulatory frameworks are established.
“I’ve watched cannabis medicine evolve in humans over two decades, and the veterinary extension makes clinical sense for animals with chronic pain or seizure disorders where conventional options have failed or caused significant side effects, but we need the same rigorous dosing protocols and safety monitoring in animals that responsible human practice requires.”
🐾 As cannabis legalization expands, veterinary medicine faces its own regulatory crossroads, with Maryland considering legislation that would permit veterinarians to recommend cannabis products for companion animals. While some pet owners and veterinarians report anecdotal benefits for pain and anxiety in dogs and cats, the evidence base remains extremely limited compared to human studies, with minimal controlled trials, no established dosing guidelines, and unclear safety profiles across species and formulations. Clinicians should recognize that pets metabolize cannabinoids differently than humans, and products marketed for animals often lack standardization or quality assurance, creating additional uncertainty about efficacy and potential toxicity. Given these gaps, veterinary practitioners encountering client interest in cannabis for their pets should remain appropriately cautious, document such discussions thoroughly, and consider cannabis as a potential option only when conventional evidence-based treatments have been exhausted, while advocating for further rigorous research to establish safety and efficacy parameters specific to animal
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: